Welcome to our dedicated page for Cactus Acquisition 1 news (Ticker: CCTSW), a resource for investors and traders seeking the latest updates and insights on Cactus Acquisition 1 stock.
Cactus Acquisition Corp 1 Ltd (CCTSW) provides investors with comprehensive coverage of corporate developments and regulatory filings related to its special purpose acquisition company mandate. This resource aggregates official announcements regarding merger targets, shareholder meetings, and leadership decisions focused on Israel's technology-driven healthcare sector.
Visitors gain access to verified updates including business combination progress reports, SEC filings, and executive team communications. The curated collection serves as a strategic monitoring tool for tracking this SPAC's activities in medical innovation and cross-border transactions.
Key content includes updates on partnership evaluations, proxy statement disclosures, and corporate governance matters. All materials are sourced from official company communications to ensure regulatory compliance and factual accuracy.
Bookmark this page for streamlined access to CCTSW's latest developments as it pursues acquisition targets in healthcare technology. Regularly updated information helps stakeholders make informed decisions based on primary source materials.
Cactus Acquisition Corp. 1 Ltd. (Nasdaq: CCTS) has announced plans for an extraordinary meeting on April 20, 2023, to vote on extending the deadline for its initial business combination from May 2, 2023, to November 2, 2023. This extension requires approval from shareholders and aims to enable further strategic opportunities. The Company’s sponsor, Cactus Healthcare Management, will contribute funds to the trust account, potentially amounting to $40,000 or $0.02 per public share. Additionally, any funds will remain untouched for excise tax payments under the Inflation Reduction Act of 2022. If approved, the Sponsor will also convert its Class B shares into Class A shares, increasing the number of outstanding Class A shares. The trust account will yield interest at approximately 4.5% per annum, although this rate may vary.
Cactus Acquisition Corp. 1 Limited (NasdaqGM: CCTS, CCTSU and CCTSW) filed its annual report on Form 10-K for the year ending December 31, 2021, with the SEC on March 31, 2022. The company is focused on mergers and acquisitions in technology-based healthcare sectors, particularly those related to Israel. Led by CEO Ofer Gonen, the firm aims to combine with innovative businesses in this space. The report and other filings can be accessed on the company website or the SEC's site.
FAQ
What is the current stock price of Cactus Acquisition 1 (CCTSW)?
